Low-Concentration Atropine for Myopia Progression (LAMP) Study
| Autor: | Jason C. S. Yam, Clement C Y Tham, Chi Pui Pang, Shu Min Tang, Antony Law, Joyce J. Chan, Alvin L. Young, Li Jia Chen, Yuning Jiang, Simon T. C. Ko, Emily S. Wong |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0303 health sciences
medicine.medical_specialty Visual acuity genetic structures business.industry medicine.medical_treatment Placebo-controlled study Eye drop Astigmatism Placebo medicine.disease eye diseases 03 medical and health sciences Ophthalmology Atropine 0302 clinical medicine 030221 ophthalmology & optometry medicine medicine.symptom business Adverse effect Dioptre 030304 developmental biology medicine.drug |
| Zdroj: | Ophthalmology. 126:113-124 |
| ISSN: | 0161-6420 |
| DOI: | 10.1016/j.ophtha.2018.05.029 |
| Popis: | Purpose Low-concentration atropine is an emerging therapy for myopia progression, but its efficacy and optimal concentration remain uncertain. Our study aimed to evaluate the efficacy and safety of low-concentration atropine eye drops at 0.05%, 0.025%, and 0.01% compared with placebo over a 1-year period. Design Randomized, placebo-controlled, double-masked trial. Participants A total of 438 children aged 4 to 12 years with myopia of at least −1.0 diopter (D) and astigmatism of −2.5 D or less. Methods Participants were randomly assigned in a 1:1:1:1 ratio to receive 0.05%, 0.025%, and 0.01% atropine eye drops, or placebo eye drop, respectively, once nightly to both eyes for 1 year. Cycloplegic refraction, axial length (AL), accommodation amplitude, pupil diameter, and best-corrected visual acuity were measured at baseline, 2 weeks, 4 months, 8 months, and 12 months. Visual Function Questionnaire was administered at the 1-year visit. Main Outcome Measures Changes in spherical equivalent (SE) and AL were measured, and their differences among groups were compared using generalized estimating equation. Results After 1 year, the mean SE change was −0.27±0.61 D, −0.46±0.45 D, −0.59±0.61 D, and −0.81±0.53 D in the 0.05%, 0.025%, and 0.01% atropine groups, and placebo groups, respectively (P Conclusions The 0.05%, 0.025%, and 0.01% atropine eye drops reduced myopia progression along a concentration-dependent response. All concentrations were well tolerated without an adverse effect on vision-related quality of life. Of the 3 concentrations used, 0.05% atropine was most effective in controlling SE progression and AL elongation over a period of 1 year. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|